Contemporary prospects of prevention of type 2 diabetes mellitus;Současné možnosti prevence diabetes mellitus 2. typu

Casopis Lekaru Ceskych

Volumn 144, Issue 3, 2005, Pages 147-151

  Zeman, Miroslav ^a,c   Zak A ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NONE   (Czech Republic)

Author keywords

Diabetes prevention; Impaired glucose tolerance; Lifestyle changes; Metabolic syndrome; Obesity; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; DIMETAMFETAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAHYDROLIPSTATIN; ANGIOTENSIN RECEPTOR;

BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIETARY INTAKE; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVENTIVE MEDICINE; REVIEW; RISK REDUCTION; DIET RESTRICTION; DRUG ANTAGONISM; GLUCOSE INTOLERANCE; METABOLISM; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 15944367693     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. International Diabetes Federation. Diabetes Mellitus and Cardiovascular Disease. Time to Act. Brussels, 2001.
2. st century. Diabetes Res. Clin. Pract., 2003, 59, s. 165-180.
3. Haffner, S. M., Stern, P., Hazuda, H. P.: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary disease start ticking before the onset of clinical diabetes? JAMA, 1990, 263, s. 2893-2898.
4. Stern, M. P.: Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes, 1995, 44, s. 369-374.
5. Reaven, G. M.: Role of insulin resistance in human disease. Diabetes, 1988, 37, s. 1595-1607.
6. Lorenzo, C., Okoloise, M., Williams, K. et al.: The metabolic syndrome as predictor of type 2 diabetes. The Santonio Heart Study. Diabetes Care, 2003, 26, s. 3153-3159.
7. Festa, A. D., Agostino, R., Howard, G. et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2000, 102, s. 42-47.
8. Dandona, P., Aljada, A., Bandyopadhyay, A.: Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 2004, 25, s. 4-7.
9. Schmidt, M. I., Duncan, B. B.: Diabesity: an inflammatory metabolic condition. Clin. Chem. Lab. Med., 2003, 41, s. 1120-1130.
10. Pickup, J. C., Mattock, M. B., Chusney, G. D., Burt, D.: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997, 40, s. 1286-1292.
11. Schmidt, M. I., Duncan, B. B., Sharrett, A. R. et al.: Markers of inflammation and prediction of diabetes melitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet, 1999, 353, s. 1649-1652.
12. American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care, 2004, 27 (Suppl. 1), s. S47-S54.
13. Mc Phillips, J. B., Berrett-Connor, E., Wingard, D. L.: Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am. J. Epidemiol., 1990, 131, s. 443-453.
14. Unwin, N., Shaw, J., Zimmet, P., Alberti, K. G.: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med., 2002, 19, s. 708-723.
15. Isomaa, B., Almgren, P., Tuomi, T. et al.: Cardiovascular morbidity et mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24, s. 683-689.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997, 20, s. 1183-1199.
17. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. Br. J. Med., 1998, 317, s. 371-375.
18. Singleton, J. R., Smith, A. G., Russell, J. W., Feldman, E. L.: Microvascular complications of impaired glucose tolerance. Diabetes, 2003, 52, s. 2867-2873.
19. Kumanyika, S., Jeffery, R. W., Morabia, A. et al.: Obesity prevention: the case for action. Int. J. Obes. Relat. Metab. Disord., 2002, 26, s. 425-435.
20. Hu, F. B., Manson, J. E., Stampfer, M. J. et al.: Diet, lifestyle and the risk of type 2 diabetes melitus in women. N. Engl. J. Med., 2001, 345, s. 790-797.
21. Pan, X., Li, G., Hu, Y. et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT Diabetes Study. Diabetes Care, 1997, 20, s. 537-544.
22. Tuomilehto, J., Lindström, J., Eriksson, J. G. et al.: Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med., 2001, 344, s. 1343-1350.
23. Diabetes Prevention Program Research Group. Reduction in the incidence of the type 2 diabetes with lifestyle intervention and metformin. N. Engl. J. Med., 2002, 346, s. 393-403.
24. Buchanan, T. A., Xiang, A. H., Peters, R. K. et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes, 2002, 51, s. 2796-2803.
25. Durbin, R. J.: Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes, Obesity and Metabolism., 2004, 6, s. 280-285.
26. Fontbonne, A., Charles, M. A., Juhan-Vague, I. et al.: The effect of metformin on the metabolic abnormalities associated with upper-body distribution. BIGPRO Study Group. Diabetes Care, 1996, 19, s. 920-926.
27. Charles, M. A., Eschwege, E.: Prevention of type 2 diabetes: role of metformin. Drugs, 1999, 58 (Suppl. 1), s. 71-73.
28. Li, C. L., Pan, C. Y., Lu, J. M.: Effect of metformin on patients with impaired glucose tolerance. Diabet. Med., 1999, 16, s. 477-481.
29. Chiasson, J. L., Josse, R. G., Gomis, R. et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 2002, 359, s. 2072-2077.
30. Torgerson, J. S., Boldrin, M. S., Hauptman, J., Sjöström, L. et al.: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 2004, 27, s. 155-161.
31. Hansson, L., Lindholm, L. H., Niskanen, L. et al.: Effect of angiotensin-converting-enzyme inhibition compared with convention therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet, 1999, 353, s. 611-616.
32. Yusuf, S., Sleight, P., Pogue, J. et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med., 2000, 342, s. 145-153.
33. Lindholm, L. H., Ibsen, H., Dahlof, B. et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, s. 1004-1010.
34. McFarlane, S. I., Kumar, A., Sowers, J. R.: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol., 2003, 91 (Suppl.), s. 30H-37H.
35. Freeman, D. J., Norrie, J., Sattar, N. et al.: Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 2001, 103, s. 357-362.
36. Haffner, S. M.: Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation, 2001, 103, s. 346-347.
37. Rosenson, R. S., Tangney, C. C., Casey, L. C.: Inhibition of proinflammatory cytokine production by pravastatin. Lancet, 1999, 353, s. 983-984.
38. Gervois, P., Pineda Torra, I., Fruchart, J.-C., Staels, B.: Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med., 2000, 38, s. 3-11.
39. Delerive, P., De Bosseher, K., Besnard, S. et al.: Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem., 1999, 274, s. 32048-32054.
40. Fukushima, M., Taniguchi, A., Sakai, M. et al.: Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care, 2000, 23, s. 259.